Inspra eplerenone: Additional Phase IIIb data

A subgroup analysis of 1,794 patients without a history of atrial fibrillation or flutter (AF/F) in the double-blind, international Phase IIIb EMPHASIS-HF trial in 2,737 patients with New York Heart Association (NYHA) class II chronic systolic heart failure showed that Inspra plus standard of care (SOC) significantly reduced the incidence of new onset AF/F vs. placebo plus SOC (2.7% vs. 4.5%, p=0.034). Patients received once-daily 25 mg Inspra or placebo for 4 weeks, at which point the dose could be increased to once-daily 50 mg based on serum potassium levels. SOC included an angiotensin-converting enzyme (ACE) inhibitor and/or angiotensin-receptor blocker (ARB), plus a beta blocker. Data were presented at the European Society of Cardiology Heart Failure Congress in Gothenburg. ...